Usted buscó: isnesiotiems (Lituano - Inglés)

gydymas kalciu isnesiotiems naujagimiams gali kelti ceftriaksono kalcio drusk nuosd rizik.
calcium treatment because of the risk of precipitation of ceftriaxone-calcium salt in term newborn.

gydymas kalciu (isnesiotiems naujagimiams yra didesn ceftriaksono kalcio drusk nuosd rizika) .
calcium treatment because of the risk of precipitation of ceftriaxone-calcium salt in term newborns.

mnesi nuo gimimo, taciau nra zinoma, ar neisnesiotiems kdikiams susidaro tokia pat gera apsauga, kaip ir isnesiotiems.
months after birth onwards but it is not known if protection against hib and menc will be as good as in children born at term.

duomenys apie poveik suaugusiems zmonms yra priestaringi, taip pat nepastebta didesnio skaiciaus su kraujavimu susijusi komplikacij atsitiktins atrankos kontroliuojam tyrim metu isnesiotiems bei beveik isnesiotiems naujagimiams su hipoksiniu kvpavimo nepakankamumu.
data in adult humans are conflicting, and there has been no increase in bleeding complications in randomised controlled trials in term and near-term neonates with hypoxic respiratory failure.

gydant interferonu alfa-2a, rhesus bezdzionms statistiskai patikimai padidjo abort daznis. nors jokio teratogeninio poveikio isnesiotiems jaunikliams nepastebta, salutinis poveikis zmonms nra paneigtas.
treatment with interferon alfa-2a resulted in a statistically significant increase in abortifacient activity in rhesus monkeys.although no teratogenic effects were seen in the offspring delivered at term, adverse effects in humans cannot be excluded.

* naujagimiams iki 13 dien amziaus mazesnis dozavimas nustatytas remiantis vidutiniais tyrim duomenimis ir gali neatitikti individualios inkst brandos variavimo.naujagimiams, isnesiotiems maziau kaip 37 savaites, dozavimo rekomendacij nra.
dosing recommendations are not available for neonates with a gestational age 37 weeks.

be to, draudziama ceftriaxone tyrol pharma 1 g svirksti raumenis jaunesniems kaip 2 met vaikams, nscioms moterims ir zindyvms.ceftriaxone tyrol pharma 1 g draudziama vartoti kalcio preparatais gydomiems isnesiotiems naujagimiams, kadangi yra ceftriaksono kalcio drusk iskritimo rizika.
ceftriaxone tyrol pharma 1g should not be used by intramuscular injection o in infants under 2 years of age and o during pregnancy and lactation ceftriaxone tyrol pharma 1g should not be used together with calcium treatment, because of the risk of precipitation of ceftriaxone-calcium salt in term newborn.

cinrgi tyrimo metu atsitiktinai atrinktiems 186 isnesiotiems ir beveik isnesiotiems naujagimiams su hipoksiniu kvpavimo nepakankamumu buvo duodama inomax (n=97) arba azoto duj (placebas; n=89) , esant pradinei 20 ppm dozei, kuri per 4­24 valandas buvo mazinama iki 5 ppm; vidutin gydymo trukm siek 44 valandas.
in the cinrgi trial, 186 term-and near-term neonates with hypoxic respiratory failure were randomised to receive either inomax (n=97) or nitrogen gas (placebo; n=89) with an initial dose of 20 ppm weaning to 5 ppm in 4 to 24 hours with median duration of exposure of 44 hours.